What is the right treatment for my cancer?
Our standalone tumour genetic profiling service can detect hundreds of DNA variants (hotspot mutations) in 26 solid tumour-associated genes. This test can be performed on very small specimens (typically 8–10 slides).
The benefits include testing for multiple genetic variants at once, rather than one by one, thus saving time by avoiding multiple tests, and identifying the correct treatment pathways more quickly.
We can also test specific genes such as EGFR, KRAS, NRAS, and BRAF individually, and perform individual gene testing by FISH.
Some testing is refundable by Medicare if requested by a specialist, such as an oncologist or a pathologist to determine whether the tumour meets requirements to access specialised chemotherapeutic drugs.
Will I have severe toxicity side effects using thiopurine drugs?
Azathioprine (AZA) and 6-mercaptopurine (6-MP) are thiopurine drugs used in the treatment of hematologic malignancies and organ transplantation, as well as other diseases such as inflammatory bowel disease (IBD) and rheumatoid arthritis. Genetic variation in the TPMT gene is associated with variation in the activity of this enzyme, and can predict the risk of serious side effects, and help to instigate a correct treatment dosage. Up to 10% of individuals have little or no enzyme activity and thus are at risk of serious and life threatening side effects from treatment. TPMT genotyping is recommended before commencing treatment with thiopurine drugs in order to prevent toxicity.
Where did my cancerous tumour originate from?
The Cancer Origin Test™ (formerly miRview® mets) can help to identify the primary tumour site in patients presenting with metastatic cancer, as well as in patients whose tumour has not been identified. As metastases need to be treated according to their primary origin, accurate identification of the metastases’ primary origin can be critical for determining appropriate treatment. The Cancer Origin Test™ identifies 25 different tumour types and pin points the metastatic tumours’ tissue of origin for correct treatment.